高碳酸血症对心脏骤停后神经功能结局的影响:一项系统评价与Meta分析
该Meta分析检索EMBASE、PubMed和WOS数据库至2023年12月5日,最终纳入7项研究2770例心脏骤停患者,比较高碳酸血症与正常碳酸血症对神经功能结局的影响。主要结局显示高碳酸血症组神经功能结局显著改善(OR 0.73;95%CI 0.56-0.96;P=0.02)。亚组分析显示短期神经功能结局高碳酸血症组优于正常碳酸血症组(OR 0.61;95%CI 0.42-0.88;P=0.008),长期无显著差异(OR 0.91;95%CI 0.76-1.10;P=0.35);两组死亡率无显著差异(OR 1.03;95%CI 0.65-1.63;P=0.91)。作者认为高碳酸血症与良好神经预后相关,尤其短期,但需进一步随机对照试验确认最佳PaCO2目标。
要点
- 纳入7项研究2770例心脏骤停患者,高碳酸血症组神经功能结局较正常碳酸血症组显著改善(OR 0.73;95%CI 0.56-0.96;P=0.02)。
- 短期神经功能结局高碳酸血症组优于正常碳酸血症组(OR 0.61;95%CI 0.42-0.88;P=0.008)。
- 长期神经功能结局两组无显著差异(OR 0.91;95%CI 0.76-1.10;P=0.35)。
- 两组死亡率无显著差异(OR 1.03;95%CI 0.65-1.63;P=0.91)。
- 当前指南推荐心脏骤停后通过通气维持正常碳酸血症;作者认为高碳酸血症与良好神经预后相关,尤其短期,但需进一步随机对照试验确认最佳PaCO2目标。
适用人群与场景
- 心脏骤停患者,比较高碳酸血症与正常碳酸血症对神经功能结局的影响。
研究设计与关键结果
- 系统评价与Meta分析,检索EMBASE、PubMed和WOS数据库至2023年12月5日,初检2137项研究,最终纳入7项研究共2770例患者。
- 主要结局:与正常碳酸血症相比,高碳酸血症显著改善心脏骤停患者神经功能结局(OR 0.73;95%CI 0.56-0.96;P=0.02)。
- 亚组分析:短期神经功能结局高碳酸血症组优于正常碳酸血症组(OR 0.61;95%CI 0.42-0.88;P=0.008);长期两组无显著差异(OR 0.91;95%CI 0.76-1.10;P=0.35)。
- 死亡率:两组无显著差异(OR 1.03;95%CI 0.65-1.63;P=0.91)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析(PROSPERO CRD42023457027,注册日期2023年9月3日)。
- 异质性I²<50%时采用固定效应模型,I²更高时采用随机效应模型。
- 局限:作者指出需进一步开展样本量充足的随机对照试验以确认最佳PaCO2目标。
对床旁实践的改变
- 当前指南推荐心脏骤停后通过通气维持正常碳酸血症。
- 作者认为高碳酸血症与良好神经预后相关,尤其短期,但需进一步随机对照试验确认最佳PaCO2目标。
指南或共识出处
- 当前指南推荐心脏骤停后通过通气维持正常碳酸血症(原文未注明具体指南名称)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Brain injury often occurs after cardiac arrest, and the regulation of PaCO2 plays a crucial role in mediating cerebral blood flow. The current guidelines recommend maintaining normocapnia through ventilation in post-arrest patients. However, the effects of hypercapnia on neurological outcomes remain controversial. To address this issue, we undertook a meta-analysis to compare the effects of hypercapnia and normocapnia on the neurological outcomes in patients with cardiac arrest.
METHODS: As of December 5, 2023, we conducted a search on eligible studies, including EMBASE, PubMed, and WOS databases. Our primary outcome of interest was a good neurological outcome, and two authors independently screened the studies and extracted relevant data. For analysis, a fixed effects model was used when the I2 values were less than 50 %, whereas a random effects model was used for higher I2 values.
RESULTS: From the 2137 studies initially identified, seven studies involving 2770 patients were ultimately included. Compared with normocapnia, hypercapnia significantly improved the neurological outcomes of patients with cardiac arrest (OR 0.73; 95 % CI 0.56-0.96; P = 0.02). According to the subgroup analysis, the hypercapnic group achieved better neurological outcomes in the short-term than did the normocapnia group (OR 0.61; 95 % CI 0.42-0.88; P = 0.008), whereas no significant difference was observed in long-term (OR 0.91; 95 % CI 0.76-1.10; P = 0.35). Moreover, there was no significant difference in mortality between the two groups (OR 1.03; 95 % CI 0.65-1.63; P = 0.91).
CONCLUSION: Our results suggest that hypercapnia is associated with a good neurological prognosis, especially in the short-term setting. However, further well-powered randomized controlled trials are necessary to confirm the optimal PaCO2 targets.
PROSPERO: CRD42023457027. Registered 3 September 2023.
参考来源
- Qiu X, Zhang Y, Wang Q, et al. Effect of hypercapnia on neurologic outcomes after cardiac arrest: A systematic review and meta-analysis. Am J Emerg Med. 2024. PMID: 39675179. doi:10.1016/j.ajem.2024.12.030
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。